You're contacting media contact of this press release

Title: Transdermal CO2 Product Demonstrates Therapeutic Potential for Numerous Conditions

Pasadena, California, United States, 29th Dec 2023 - Circularity Healthcare, an emerging leader in the health care industry, has announced a significant breakthrough in the treatment of chronic pain and underlying conditions such as fibromyalgia, arthritis, and non-healing diabetic foot wounds. This innovation, D'OXYVA® (deoxyhemoglobin vasodilator), a non-prescription, non-opioid solution, has shown remarkable results in alleviating severe chronic pain and enhancing cardiovascular, microvascular, and autonomic nervous system health.The company's approach has been especially effective for individuals struggling with severe neuropathy, chronic pain, fibromyalgia, arthritis, and various other chronic conditions. D'OXYVA®'s efficacy stems from its patented and patent pending formulation that utilizes carbon dioxide (CO2) also sourced from carbon capture processes as the main FDA-cleared active pharmaceutical ingredient (API). This not only makes the product environmentally sustainable, producing virtually zero waste, but also highly effective in treating the targeted conditions.Circularity Healthcare's commitment to affordable and accessible treatment aligns with the needs of most income levels, particularly when used as directed. The company has prioritized direct-to-consumer marketing, focusing on out-of-pocket business models that make the treatment more accessible to a wider range of patients.The product has undergone extensive testing and research, demonstrating its safety and efficacy. Over 1 million applications of D'OXYVA® have been recorded in several dozen countries, with significant involvement from 18 of the top 20 U.S. universities in expanded pivotal trials. These trials have further established the product's credibility and effectiveness, reinforcing it...

This press release is issued by King Newswire